NCT03901963 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 200
- units
- Participants
- groups
- description
- Participants received daratumumab 1800 milligrams (mg) subcutaneous (SC) injection weekly during Cycle 1 and Cycle 2 (that is, on Day 1, Day 8, Day 15 and Day 22 of each Cycle), followed by every-2-week dosing from Cycle 3 to Cycle 6 (that is, on Weeks 9, 11, 13, 15, 17, 19, and 21) and then every-4-week dosing from Cycle 7 onwards (that is, from Week 25). In addition, participants received maintenance therapy with lenalidomide 10 mg capsule orally (PO) from Day 1 to 28 in each treatment cycle. Participants received study treatment until confirmed disease progression (PD), unacceptable toxicity, or until end of study treatment, whichever occurred first. After Cycle 3, if lenalidomide was well tolerated, dose might be increased to 15 mg at the discretion of the investigator. Each treatment cycle was of 28 days.
- id
- BG000
- title
- Daratumumab + Lenalidomide
- description
- Participants received lenalidomide 10 mg capsule PO as maintenance therapy from Day 1 to Day 28 of each 28-day treatment cycle until confirmed PD, unacceptable toxicity, or the end of the study treatment, whichever occurred first. After Cycle 3, if lenalidomide was well tolerated, dose might be increased to 15 mg at the discretion of the investigator.
- id
- BG001
- title
- Lenalidomide
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.12
- value
- 61.3
- group Id
- BG001
- spread
- 9.54
- value
- 60.8
- group Id
- BG002
- spread
- 8.84
- value
- 61
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 81
- title
- Female
- measurements
- group Id
- BG000
- value
- 61
- group Id
- BG001
- value
- 58
- group Id
- BG002
- value
- 119
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 15
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 81
- group Id
- BG001
- value
- 89
- group Id
- BG002
- value
- 170
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 15
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 6
- title
- Asian
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 44
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 67
- group Id
- BG001
- value
- 68
- group Id
- BG002
- value
- 135
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- Unknown or Not Reported
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 97
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 198
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 99
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 200
- units
- Participants
- groups
- description
- Participants received daratumumab 1800 milligrams (mg) subcutaneous (SC) injection weekly during Cycle 1 and Cycle 2 (that is, on Day 1, Day 8, Day 15 and Day 22 of each Cycle), followed by every-2-week dosing from Cycle 3 to Cycle 6 (that is, on Weeks 9, 11, 13, 15, 17, 19, and 21) and then every-4-week dosing from Cycle 7 onwards (that is, from Week 25). In addition, participants received maintenance therapy with lenalidomide 10 mg capsule orally (PO) from Day 1 to 28 in each treatment cycle. Participants received study treatment until confirmed disease progression (PD), unacceptable toxicity, or until end of study treatment, whichever occurred first. After Cycle 3, if lenalidomide was well tolerated, dose might be increased to 15 mg at the discretion of the investigator. Each treatment cycle was of 28 days.
- id
- BG000
- title
- Daratumumab + Lenalidomide
- description
- Participants received lenalidomide 10 mg capsule PO as maintenance therapy from Day 1 to Day 28 of each 28-day treatment cycle until confirmed PD, unacceptable toxicity, or the end of the study treatment, whichever occurred first. After Cycle 3, if lenalidomide was well tolerated, dose might be increased to 15 mg at the discretion of the investigator.
- id
- BG001
- title
- Lenalidomide
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.12
- value
- 61.3
- group Id
- BG001
- spread
- 9.54
- value
- 60.8
- group Id
- BG002
- spread
- 8.84
- value
- 61
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 81
- title
- Female
- measurements
- group Id
- BG000
- value
- 61
- group Id
- BG001
- value
- 58
- group Id
- BG002
- value
- 119
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 15
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 81
- group Id
- BG001
- value
- 89
- group Id
- BG002
- value
- 170
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 15
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 6
- title
- Asian
- measurements
- group Id
- BG000
- value
- 20
- group Id
- BG001
- value
- 24
- group Id
- BG002
- value
- 44
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 67
- group Id
- BG001
- value
- 68
- group Id
- BG002
- value
- 135
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- title
- Unknown or Not Reported
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 8
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 97
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 198
- title
- United States
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle